MiMedx Q4 net sales $74.4M, up 10.3% YoY; adjusted EBITDA $7.3M; new CEO Capper appointed

MIMEDX GROUP, INC.

2022-FY EPS reported -$0.33 revenue$267,841,000

Q4 net sales $74.4M (+10.3% YoY); full year $267.8M (+3.6%). Highest quarterly since Q4 2019.
Q4 net loss $0.4M vs net income $2.2M in prior year; FY net loss $30.2M vs $10.3M.
Adjusted EBITDA Q4 $7.3M (improved from $3.6M); FY adjusted EBITDA $3.9M (from $18.7M).
Appointed Joseph H. Capper as CEO and Director; Ricci S. Whitlow as COO.
Commenced first registrational trial of mDHACM for knee osteoarthritis; launched EPIFIX in Japan via GUNZE.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

MIMEDX GROUP, INC. reported Full year ended December 31, 2022 results: revenue Net sales of $267.8 million for full year 2022, net income Net loss of $30.2 million for full year 2022, EPS Net (loss) income per common share - basic and diluted of ($0.33).

Period: Full year ended December 31, 2022
Revenue: Net sales of $267.8 million for full year 2022
Net income: Net loss of $30.2 million for full year 2022
EPS: Net (loss) income per common share - basic and diluted of ($0.33)
Result: reported results

Exact text from the filing

Three Months Ended December 31, Twelve Months Ended December 31, (in thousands) (in thousands) 2022 2021 2022 2021 Net sales $ 74,375 $ 67,409 $ 267,841 $ 258,615 Net (loss) income (415 ) 2,215 (30,197 ) (10,285 ) EBITDA 1 2,043 4,427 (20,929 ) 125 Adjusted EBITDA 1 7,317 3,609 3,914 18,726 Net (loss) income per common share - basic $ (0.02 ) $ 0.01 $ (0.33 ) $ (0.15 )

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

MIMEDX GROUP, INC. reported Fourth quarter ended December 31, 2022 results: revenue Net sales of $74.4 million for fourth quarter 2022, net income Net loss of $0.4 million for fourth quarter 2022, EPS Net (loss) income per common share - basic and diluted of ($0.02).

Period: Fourth quarter ended December 31, 2022
Revenue: Net sales of $74.4 million for fourth quarter 2022
Net income: Net loss of $0.4 million for fourth quarter 2022
EPS: Net (loss) income per common share - basic and diluted of ($0.02)
Result: reported results

Exact text from the filing

Three Months Ended December 31, Twelve Months Ended December 31, (in thousands) (in thousands) 2022 2021 2022 2021 Net sales $ 74,375 $ 67,409 $ 267,841 $ 258,615 Net (loss) income (415 ) 2,215 (30,197 ) (10,285 ) EBITDA 1 2,043 4,427 (20,929 ) 125 Adjusted EBITDA 1 7,317 3,609 3,914 18,726 Net (loss) income per common share - basic $ (0.02 ) $ 0.01 $ (0.33 ) $ (0.15 )

View on SEC.gov

Browse all earnings releases →

MIMEDX GROUP, INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-053829

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.